RE:RE:Hold it Baby...I don't know when it will leave $3 in the rearview mirror, but it is inevitable.
But to give you an idea of what THTX is up against, as well as the future potential, I just read a NASH industry report from Piper that had an exhaustive list of all the NASH trials and companies in it. THTX was not to be found on it (unless I am blind). The good news is that will not be the case the next time the report is updated but it shows how you can get ignored when you come through the NASH ranks on the back of NIH, rather than company sponsored trials and when you switch to general NASH from HIV NASH at the last minute.
It really is quite increidble the company is a phase III NASH player given its history of development in HIV NASH. Management deserves a ton of credit for pulling that rabbit out of the hat. Now, we just have to get the analysts focusing on that very attractive rabbit!
BTW - no reports from Canaccord or Mackie yet that Bloomberg has seen.
Wino115 wrote: We broke $3, I would love to see it put the $2 handle in our rear view mirror for good! Please Hold Baby!
Wino115 wrote: I would love to see it hold a US$3 handle today for once. It's been 2 years of not being able to hold breakouts. I have been consistent in saying they need to have true value-enhancing developments that should lead to concrete and incontrovertible market cap support. We're seeing a bit of it today and beginning to walk down those paths. The biggest supports are still to come. But if we can eliminate the "downside" that it's worth $2 something and slowly narrow the future value focus into view at higher levels, we may be on that path of gaining some share price momentum back in to it which all the portfolio managers younger than 50 want to see before they buy. Let's hold that $3 level today!!